8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

   PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

                                NOVEMBER 20, 2003
                Date of Report (date of Earliest Event Reported)


                                 ISOLAGEN, INC.
             (Exact Name of Registrant as Specified in its Charter)


           DELAWARE                      0-12666                87-0458888
(State or Other Jurisdiction of    (Commission File No.)     (I.R.S. Employer
 Incorporation or Organization)                             Identification No.)


                 2500 WILCREST, 5TH FLOOR, HOUSTON, TEXAS 77042
              (Address of principal executive offices and zip code)

                                 (713) 780-4754
              (Registrant's telephone number, including area code)


                                 NOT APPLICABLE
          (Former name or former address, if changed from last report)



ITEM 5.  OTHER EVENTS.

         On November 20, 2003 the Company issued a press release relating to
positive results in the United Kingdom. The press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference. The reader is advised to
read the press release in its entirety.


                          [THE SIGNATURE PAGE FOLLOWS.]



                                    SIGNATURE

         Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                         ISOLAGEN, INC.


Date:    November 20, 2003               By:  /s/ Jeffrey W. Tomz
                                              ---------------------------------
                                              Chief Financial Officer



                                 EXHIBIT INDEX


EXHIBIT NUMBER          DESCRIPTION
- --------------          -----------

    99.1                Press Release dated November 20, 2003.

EX-99.1

                                                                   EXHIBIT 99.1

THURSDAY, NOVEMBER 20, 2003, 9:00 AM EASTERN TIME

PRESS RELEASE

SOURCE:  Isolagen, Inc.

ISOLAGEN SHOWS POSITIVE RESULTS IN THE UK

HOUSTON, T.X. - (PRNewswire) - November 20, 2003 - Isolagen, Inc. (AMEX: ILE), a
biopharmaceutical company specializing in the development and commercialization
of autologous cellular therapy for hard and soft tissue regeneration, is pleased
to announce that it has received data from an independent clinical research
organization demonstrating positive results from patients treated with the
Isolagen Process in the United Kingdom ("UK").

Isolagen collected patient response data from 59 patients randomly chosen from a
total of the approximately 400 patients treated to date in the UK with the
Isolagen Process. This data was independently analyzed by an independent
clinical research organization. The preliminary data analysis shows positive
results. The sampling reflects a cross section of all treated patients at all
stages of treatment rather than a summary of patients at some fixed time point
following administration of treatment. This data will be part of a submission
package that will be presented to the United States Food and Drug Administration
("FDA") for a trial design discussion in December of this year.

The results indicate that 73% of sampled patients tested demonstrated positive
results even in the first two months of therapy while still receiving
injections. One hundred percent of the patients tested who received the Isolagen
Process treatment for 6 months or longer had positive results. Very few adverse
events were reported and these included mild edema and redness at the injection
site, which resolved spontaneously. Collection of data is continuing and the
patient data will be incorporated into the proposed International Patient
registry for FDA regulatory purposes.

ABOUT ISOLAGEN, INC.

Isolagen, Inc. (AMEX: ILE) is the parent company of Isolagen Technologies, Inc.,
which was founded in 1995. Isolagen has focused its efforts in the development
of autologous cellular technology that has specific applications in cosmetic
dermatology and is exploring applications for periodontal disease,
reconstructive dentistry and other health-related markets.

Autologous cellular therapy is a process whereby a patient's own cells are
extracted, reproduced and then reintroduced to the patient for specific cosmetic
and medical applications. Unlike other applications for the treatment of dermal
defects, Isolagen utilizes only the patient's unique, living cells to produce
the patient's own collagen. There is no foreign substance utilized in this
treatment protocol. Isolagen's goal is to become the industry leader in the
research, development and commercialization of autologous cellular therapy.



This press release contains forward-looking statements and general statements
relating to the development of autologous cellular therapy that has specific
applications in cosmetic dermatology and also relating to the exploration of
applications for periodontal disease, reconstructive dentistry and other
health-related markets. The discovery and development of applications for
autologous cellular therapy are subject to substantial risks and uncertainties.
There can be no assurance that Isolagen's clinical trials relating to autologous
cellular therapy applications for the treatment of dermal defects or gingival
recession can be conducted within the timeframe that Isolagen expects, that such
trials will yield positive results, or that additional applications for the
commercialization of autologous cellular therapy can be identified and advanced
into human clinical trials. These and other factors, including, but not limited
to those described in Isolagen's most recent annual report on Form 10-KSB/A
filed with the Securities and Exchange Commission, could cause future results to
differ materially from the expectations expressed in this press release. The
forward-looking statements contained in this press release may become outdated
over time. Isolagen does not assume any responsibility for updating any
forward-looking statements.

Isolagen's corporate headquarters are located in Houston, TX. For further
information, please see www.isolagen.com.

Contact:
Isolagen, Inc.
Michael Macaluso, CEO 713-780-4754
Jeffrey W. Tomz, CFO 713-780-4754